CSU

Triple-I Stresses Preparedness for ‘Very Active’ 2024 Atlantic Hurricane Season

Retrieved on: 
Friday, May 3, 2024
Natural Disasters, Environment, Professional Services, Climate Change, Insurance, Clothing, Small business, Element, NOAA, Policy, Cyclone, Insurance Information Institute, Theft, Research, Water, Disaster, Colorado State University, Building material, Wind, Tree, Condo, Electronics, Loss, National Hurricane Preparedness Week, CSU, NFIP

A typical Atlantic hurricane season has 14 named storms, seven hurricanes and three major hurricanes.

Key Points: 
  • A typical Atlantic hurricane season has 14 named storms, seven hurricanes and three major hurricanes.
  • With more Americans living in harm’s way than ever before, it is critical for everyone residing in a hurricane-prone community to make preparedness a priority for the upcoming season,” Kevelighan added.
  • National Hurricane Preparedness Week , spearheaded by the National Oceanic and Atmospheric Administration (NOAA), starts on Sunday, May 5, and continues through Saturday, May 11.
  • The Triple-I’s four key hurricane preparedness tips for the 2024 season include:
    Review Your Insurance Coverage.

Newark Native Mohamed Kamara Selected as 158th Draft Pick by the Miami Dolphins

Retrieved on: 
Wednesday, May 1, 2024
NFL, Miami Dolphins, Colorado State University, Central High School, Master, Bachelor, Athlete, National Football League Draft, Human development, CSU, Nursing

His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.

Key Points: 
  • His athleticism continued post-graduation when he committed to Colorado State University (CSU) as a 3-star recruit.
  • At CSU, he exceeded expectations, earning the title of Mountain West Defensive Player of the Year.
  • On Saturday, April 27, 2024, his journey reached new heights when he was selected by the Miami Dolphins as the 158th pick in the NFL Draft, a testament to his skill, determination, and passion for the game.
  • "We are ecstatic to witness Mohamed Kamara's ascent in his football career," exclaimed Principal Terri Mitchell.

Colorado State University Global’s Teaching and Learning Programs Impact K-12 Education in Colorado

Retrieved on: 
Thursday, April 18, 2024
Online, CO, Vice-principal, Certification, News, School, Colorado State University–Global Campus, Student, History, CSU, K-12, MSTL, Nursing

The programs’ educational and hands-on learning advancement opportunities empower educators across the state and beyond, to make a difference in their personal lives, classrooms, and communities.

Key Points: 
  • The programs’ educational and hands-on learning advancement opportunities empower educators across the state and beyond, to make a difference in their personal lives, classrooms, and communities.
  • That’s why we’ve created flexible programs that allow educators to advance their careers without having to step away from the classroom.
  • What’s more, its PL program is the only 100% online program of its kind authorized by the state of Colorado.
  • Further, graduates can transfer those credits into a Master’s Degree in Teaching and Learning, reducing their time and costs to degree completion.

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Retrieved on: 
Wednesday, April 17, 2024
Patient, Safety, Skin, Survival, CFT, CTT, Disease, Week, KIT, Temperature, Therapy, CSU, Pharmaceutical industry

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).

Key Points: 
  • HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
  • Mast cell activation is known to be a critical driver in ColdU and SD.
  • In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticaria (CSU).
  • "We are very grateful to all the investigators and patients who supported this trial," said Anthony Marucci, President and Chief Executive Officer of Celldex Therapeutics.

Conduent Completes Sale of its Curbside Management and Public Safety Businesses to Modaxo

Retrieved on: 
Wednesday, May 1, 2024
Software, Human Resources, Artificial Intelligence, Public Transport, Professional Services, Technology, Transport, Digital Cash Management, Digital Assets, Constellation, Sale, TSX, Conduent, CSU

Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, today announced it has successfully completed the sale of its Curbside Management Solutions and Public Safety Solutions businesses to Modaxo , a division of Constellation Software Inc. (TSX: CSU).

Key Points: 
  • Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, today announced it has successfully completed the sale of its Curbside Management Solutions and Public Safety Solutions businesses to Modaxo , a division of Constellation Software Inc. (TSX: CSU).
  • Conduent will also continue to drive innovation in its Road Usage Charging Solutions and Transit Solutions businesses to enable streamlined, high-volume mobility services.
  • The sale to Modaxo has no impact on these businesses.
  • Additional details of the transaction are outlined in Conduent’s 8-K filed with the U.S. Securities and Exchange Commission (SEC) today.

Key Appointments Strengthen Our Commitment to Security Excellence and Unwavering Law Enforcement Support

Retrieved on: 
Thursday, April 25, 2024
Software, Networks, Data Management, Technology, Apps, Applications, Mobile, Wireless, Other Technology, Security, Education, Organization, Law enforcement, Head, IACP, Safety, Teaching, CPP, Organized crime, Newport Beach, California, Real Time Crime Center, International Association, Senior, Record, NYPD, ASIS International, Police, Real-time, CSU, Wren, Private investigator

With two decades of service to our organization and as the founder of our Law Enforcement Division, Richard consistently displays his commitment and expertise in enhancing our partnerships in the Law Enforcement sector.

Key Points: 
  • With two decades of service to our organization and as the founder of our Law Enforcement Division, Richard consistently displays his commitment and expertise in enhancing our partnerships in the Law Enforcement sector.
  • Joe’s extensive law enforcement background and deep connections within the security community will contribute to strengthening partnerships across law enforcement and commercial sectors.
  • He stated, "Joe’s and Henry’s deep expertise and proven track records are invaluable as we integrate cutting-edge technologies with law enforcement operations.
  • These strategic appointments underscore 3SI + Wren’s commitment to fostering safer communities and business environments through innovative technology and collaborative strategies.

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Goldman Sachs, American Academy, Hart–Scott–Rodino Antitrust Improvements Act, B cell, LLP, Safety, Skin, Vital signs, Centerview Partners, Research, ECG, Covington & Burling, MRGPRX2, MRGPRX4, Autoimmunity, Therapy, Science, Escient, Incidence, Patient, Acquisition, Multimedia, Atopic dermatitis, CSU

This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Key Points: 
  • This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “These drug candidates are the result of the highly innovative research performed by Escient’s employees and scientific collaborators,” said Joshua A. Grass, President and Chief Executive Officer, Escient.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction and Fenwick & West LLP acted as legal counsel for Escient.
  • The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415.

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Employment, Conference, Option, CSU, News, Therapy, Event, CD117

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.

Key Points: 
  • REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
  • A live webcast of the presentation will be available on the Events & News – Presentations page of Jasper's Investor Relations website.
  • An archived replay of the presentation will be available on Jasper's website for 30 days following the live broadcast.
  • Each Option was granted pursuant to the Jasper Therapeutics, Inc.

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Thursday, March 21, 2024
CD117, News, Conference, Therapy, Event, CSU

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.

Key Points: 
  • REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.
  • A live webcast of the fireside chat will be available on the Events & News – Presentations page of Jasper's Investor Relations website.
  • An archived replay of the fireside chat will be available on Jasper's website for 30 days following the live broadcast.

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Retrieved on: 
Tuesday, March 19, 2024
Patient, Cold urticaria, CSU, Trial of the century, B cell, Therapy, Safety, Pharmacokinetics, CD117, Pharmaceutical industry

REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.

Key Points: 
  • REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.
  • The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
  • “We are excited to announce dosing of the first patient in the SPOTLIGHT study in patients with CIndU, our second clinical program evaluating briquilimab in a mast cell-mediated disease,” said Edwin Tucker, Chief Medical Officer of Jasper.
  • Jasper anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024.